Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

IDMC of phase II study of EscharEx for venous leg ulcers recommends continuation of trial

July 29, 2021

Dosing underway in phase I trial of AR degrader GT-20029 in China

July 28, 2021

Leo Pharma begins phase IIa study of LEO-138559 for moderate to severe atopic dermatitis

July 27, 2021

PolarityTE submits IND for SkinTE in chronic cutaneous ulcers

July 27, 2021

Gilead studies GS-5718 in phase Ib for cutaneous lupus erythematosus

July 23, 2021

Dosing commences in phase II study of STP-705 for keloid scar prevention

July 15, 2021

Escient reports phase I data on EP-547 for pruritus associated with cholestasis and uremia

July 15, 2021

HT-003 reduces expression of inflammatory cytokines in acne therapeutic model

July 15, 2021

FDA clears IND for Kintor's GT-20029 for androgenetic alopecia and acne

July 14, 2021

Tyrosine-protein kinase ITK/TSK inhibitors discovered at Pfizer

July 14, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...